Management tracks: BioMarin's first chief scientific strategy officer; plus Ascletis, Grail, Aerie and more

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) promoted Lon Cardon to the newly created role of chief scientific strategy officer from CSO. Prior to BioMarin, Cardon was SVP of alternative discovery and development and head of target sciences at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK).

Antiviral and cancer company Ascletis Pharma Inc. (HKSE:1672) hired Handan He as CSO. She was global head of computational, biopharmaceutics and translational PK/PD at the Novartis Pharmaceuticals Corp. affiliate of Novartis AG (NYSE:NVS; SIX:NOVN)...